

Docket No.: 59849(47992)

(PATENT)

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Jeffrey Schlom et al.	
Application No.: 10/582,702	Confirmation No. 1000
Filed: June 12, 2006	Confirmation No.: 4962
For: HUMAN CYTOTOXIC T-LYMPHOCTYE EPITOPE AND ITS AGONIST EPTIOPE FROM THE NON-VARIABLE NUMBER OF TANDEM REPEAT SEQUENCE OF MUC-1	Art Unit: N/A  Examiner: Not Yet Assigned

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

(check and complete this item, if applicable)

1. [	This replies to the Office Letter DATED
NOTE:	If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.
	[ ] A copy of the Office Letter is enclosed.

### **IDENTIFICATION OF PERSON MAKING STATEMENT**

2.	l, _	Christi	ne C. O'Day	
	(type or print name of person signing below)			
	sta	te the f	ollowing:	
			ITEMS BEING SUBMITTED	
3.	Sul	bmitted	herewith is/are	
			(check each item as applicable)	
	A.	[X] "Se	equence Listing(s)" for the nucleotide and/or amino application. Each "Sequence Listing" is assigned a se in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.8	eparate identifier as required
	B.	[]	An amendment to the description and/or claims, wher sequence by use of the assigned identifier, as required	
	C.	[]	A copy of each "Sequence Listing" submitted for readable form, in accordance with the requirements of 1.824.	
	D. [ ] Please transfer to this application, in accordance with 37 C.F.R. § 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:			
lde		•	outer readable form(s) of applicant's other application co f the application as follows:	orresponds to the "Sequence
<b>{</b>	PRI\	/ATE }	Computer Readable Form	"Sequence Identifier"
(other application) (this application			(this application)	
S	SEQ ID NO: SEQ ID NO:			

NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference maybe made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new

application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. § 1.821(e). E. [X] A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g). [ ] Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. § 1.821(b). F. [X] Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter. [ ] Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. § 1.821(g). STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER 4. I hereby state: (complete applicable item A and/or B) A. [ ] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate. B. [ ] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter. **STATUS** 5. Applicant is [ ] a small entity. A statement: [ ] is attached. [ ] was already filed. [X ] other than a small entity. **EXTENSION OF TERM** 

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been

additional amendment after expiration of the shortened statutory period.

filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an

6.

(Submission-Nucleotide and/or Amino Acid Sequence-page 3 of 5)

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec.10, 1985 (1061 O.G. 34-35).

7.	7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. § 1.136			16		
	apply.					
			(complete (a) or (b	) as	s applicable)	
(a) [ ] Applicant petitions for an extension of time under 37 C.F.R. § 1.136 (fees: 37 C.F.R. § 1.17(a)(1)-(4)) for the total number of months checked below:						
		Extension (months)	Fee for other than small entity		Fee for small entity	
	[]	one month two months three months four months	\$870.00	\$ \$	5 55.00 5 190.00 6 435.00 6 680.00	
Fee \$						
If an additional extension of time is required, please consider this a petition therefor.						
(check and complete the next item, if applicable)						
[ ] An extension for months has already been secured, and the fee paid therefor of \$ is deducted from the total fee due for the total months of extension now requested.			id of			
	Extension fee due with this request \$					

**OR** 

overlooked the need for a petition and fee for extension of time.

(b) [X]


Applicant believes that no extension of term is required. However, this conditional

petition is being made to provide for the possibility that applicant has inadvertently

## **FEE PAYMENT**

8. []	Attached is a check in the sum of \$		
[]	Charge Account No the sum of A duplicate of this transmittal is attached.	of \$	
	FEE DEFIC	IENCY	
9.  NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.			
10. [X	If any additional extension and/or fee is requ	ired, charge Account No04-1105	
SIGNATURE(s)			
DATE: September 24, 2007		Christine C. O'Day (Reg. 38,256) Attorney for Applicants EDWARDS ANGELL PALMER &DODGE LLP P.O. Box 55874 Boston, MA 02205	
	: (617) 239-0100 No. 38,256	<ul> <li>[ ] Inventor</li> <li>[ ] Assignee of complete interest</li> <li>[ ] Person authorized to sign on behalf of assignee</li> <li>[ X ] Practitioner of record</li> <li>[ ] Filed under Rule 34(a)</li> <li>[ ] Registration No.</li> <li>[ ] Other</li> </ul>	

BOS2\_633113.1



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

U.S. APPLICATION NUMBER NO.

FIRST NAMED APPLICANT

ATTY. DOCKET NO.

10/582,702

Jeffrey Schlom

59849(47992)

INTERNATIONAL APPLICATION NO.

PCT/US04/41921

I.A. FILING DATE

PRIORITY DATE

12/10/2004

12/12/2003

CONFIRMATION NO. 4962 **371 FORMALITIES LETTER** 

\*OC000000025486878\*

21874 **EDWARDS ANGELL PALMER & DODGE LLP** P.O. BOX 55874 BOSTON, MA 02205

Date Mailed: 08/22/2007

#### NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Priority Document
- Copy of the International Application filed on 06/12/2006
- Copy of the International Search Report filed on 03/22/2007
- Preliminary Amendments filed on 06/12/2006
- Information Disclosure Statements filed on 06/12/2006
- Biochemical Sequence Diskette filed on 04/23/2007
- Oath or Declaration filed on 04/23/2007
- U.S. Basic National Fees filed on 06/12/2006
- Assignment filed on 03/22/2007
- Priority Documents filed on 06/12/2006
- Power of Attorney filed on 04/23/2007
- Specification filed on 06/12/2006
- Claims filed on 06/12/2006
- Abstracts filed on 06/12/2006
- Drawings filed on 06/12/2006

Applicant's response filed 04/23/2007 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 02/22/2007 have not been completed.

• This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where

applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825 (d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821 (e) may be submitted in lieu of a new CRF.

A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as
indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
of the sequence listing information recorded in computer readable form is identical to the written (on paper
or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. <a href="https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html">https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html</a>

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at <a href="http://www.uspto.gov/ebc.">http://www.uspto.gov/ebc.</a>

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

SHAKEEL AHMED

Telephone: (703) 308-9140 EXT 208

#### PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/582,702	PCT/US04/41921	59849(47992)

FORM PCT/DO/EO/916 (371 Formalities Notice)

PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# **TRANSMITTAL FORM**

(to be used for all correspondence after initial filing)

Application Number 10/582,702-Conf. #4962 Filing Date June 12, 2006 First Named Inventor Jeffrey Schlom Art Unit N/A Examiner Name Not Yet Assigned Attorney Docket Number 59849(47992)

Total Number of Pages in This Submission ENCLOSURES (Check all that apply) After Allowance Communication Drawing(s) Fee Transmittal Form Appeal Communication to Board of Licensing-related Papers Fee Attached Appeals and Interferences Appeal Communication to Petition X Amendment/Reply

		(Appeal Notice, Brief, Repi
After Final	Petition to Convert to a Provisional Application	Proprietary Information
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter
Extension of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please Identify below):
Express Abandonment Request	Request for Refund	Submission of "Sequence Computer Readable Cop
Information Disclosure Statement	CD, Number of CD(s)	Sequence Listing Paper   Sequence Listing Disket
Certified Copy of Priority Document(s)	Landscape Table on CD	Notification of Defective Return Receipt Postcard
X Reply to Missing Parts/ Incomplete Application	Remarks	
Reply to Missing Parts under 37 CFR 1.52 or 1.53	·	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT EDWARDS ANGELL PALMER & DODGE LLP

Mix Ch Printed name Christine C. O'Day

Firm Name

Signature

Date September 24, 2007 Reg. No. 38,256





Application No. (if known): 10/582,702

Attorney Docket No.: 59849(47992)

# Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EM054389368US in an envelope addressed to:

MS Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

September 24, 2007

Date

	l M		
(/1 mm 2,	9/1grass		
Signature			
Lynn Marcus			
Typed or printed name of person signing Certificate			
	(617) 239-0100		
Registration Number, if applicable	Telephone Number		

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page)

Supplemental Preliminary Amendment (3 pages)

Response to Notification of Defective Response (2 pages)

Submission of "Sequence Listing," Computer Readable Copy, And/Or Amendment Pertaining Thereto for Biotechnology Invention Containing

Nucleotide And/Or Amino Acid Sequence (5 pages)

Sequence Listing Paper Copy (9 pages)

Sequence Lising (Diskette)

Copy of Notification of Defective Response (2 pages)